Pfizer shares (PFE.US) gain nearly 2% following the announcement that the company will buy a license for a new immuno-oncology therapy from Chinese biotech giant 3SBio Inc. The $1.25 billion upfront payment marks the largest licensing deal of its kind with a Chinese pharmaceutical company.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appPfizer shares are rebounding from the second low that hit the biotech sector after Donald Trump signed an executive order on prescription drug pricing. The stock has broken above its 30-day exponential moving average (EMA30, light purple), though gains have stalled at the 23.6% Fibonacci retracement level. A potential breakout above the 100-day EMA (dark purple) would be key to returning to the recent consolidation zone. Source: xStation5
The Start of a Close Partnership
The therapy at the center of the deal, SSGJ-707, is an innovative cancer treatment that both stimulates the immune system to fight tumors and inhibits the formation of new blood vessels critical to tumor growth. The therapy is currently undergoing clinical trials for multiple tumor types, with late-stage studies expected to begin in China by the end of 2025.
The licensing deal marks the beginning of a broader collaboration and reflects Pfizer’s growing interest in Chinese biotech innovation. Clinical milestone payments could total up to $4.8 billion, and the American pharma giant also plans to invest approximately $100 million in 3SBio. Pfizer will be responsible for manufacturing the therapy in the U.S. and handling its global distribution.
Overpayment or Strategic Investment?
Compared to a similar transaction by Merck ($588 million upfront + $2.7 billion in milestone payments), Pfizer appears to be paying a premium for its relatively late entry into the next-gen oncology therapy space. Following recent changes in its capital structure and a general decline in stock price since the COVID-19 pandemic, the deal holds fundamental strategic importance to secure Pfizer’s position in a fast-growing market.
A Deal That Defies Protectionism
The growing interest in pharmaceutical innovation from China contrasts with the rising U.S. isolationism, particularly in healthcare and drug sourcing. Donald Trump has repeatedly emphasized the need to reduce dependency on drugs made in Asia — especially in China and India — while also questioning their quality and safety. In consequence, the deal has sparked optimism in China’s pharmaceutical sector—the Hang Seng healthcare subindex outperformed the broader Chinese market today, gaining 3.8%.
Despite relatively stable revenue in recent quarters, Pfizer shares remain under pressure due to intense competition and the lack of a breakthrough drug pipeline. With a forward P/E ratio of 8.4, the company remains relatively cheap compared to the broader pharma sector and the S&P 500 index overall.Source: XTB Research
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
